[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Pittsburgh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":647},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,164,0,25,[9,45,67,91,119,141,160,185,205,228,251,284,305,332,366,394,421,440,462,488,511,536,564,594,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645953","preventing-lymphedema-in-patients-undergoing-surgical-treatment-for-head-and-neck-cancer-through-vein-reconstruction-100645953",false,"NCT07694726","Preventing Lymphedema in Patients Undergoing Surgical Treatment for Head and Neck Cancer Through Vein Reconstruction","Lymphedema Prevention With Facial Vein Preservation or Reconstruction During Neck Dissection for Operable Head & Neck Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Ability to comply with the study protocol, including follow up visits and additional requirements for data collection\n* Ability to provide informed consent\n* Patients requiring unilateral or bilateral neck dissection. Patients must undergo at least three level neck dissection which must include level 1B\n* Patients will undergo radiotherapy +\u002F-chemotherapy after surgery for HNC. Patients will be required to have adjuvant therapy after surgery to have similar risk of development of lymphedema.\n* No history of allergy to indocyanine green.\n\nExclusion Criteria:\n\n* Shellfish Allergy\n* Contraindication to surgery under general anesthesia\n* Prior head and neck surgery, radiation, or chemotherapy for HNC\n* Patients requiring sacrifice of the internal jugular vein or resection of neck skin for oncologic care\n* Anticipated partial or total laryngectomy\n* Pregnancy or lactation","ALL","18 Years",{"count":20,"type":21},37,"ESTIMATED","INTERVENTIONAL",[24],"NA","\\* The goal of this clinical trial is to learn if facial vein reconstruction after neck dissection works to reduce rates of lymphedema in adults getting surgical treatment for head and neck cancer.\n\nThis is a trial which aims to improve the rate of lymphedema for patients undergoing treatment for head and neck cancer. Our aim is to re-establish venous flow across the facial vein to improve lymphatic drainage after neck dissection.\n\n* The investigators will also evaluate lymphatic flow before and after facial vein reconstruction to determine if there is evidence of lymphedema.\n* The main questions this study aims to answer are:\n\n  1. Does facial vein reconstruction after neck dissection improved lymphatic flow in head and neck cancer patients?\n  2. Determine if there are changes in lymphatic flow before and after facial vein reconstruction?\n\nAfter the study is completed, the investigators will compare rates of lymphedema and quality of life in patients with facial vein preservation\u002Freconstruction as compared to previous patients treated for head and neck cancer without facial vein reconstruction.\n\nParticipants will undergo the following:\n\n1. Oncologic and reconstructive surgery as normal. No changes in cancer treatment will occur due to the study.\n2. When necessary, participants will undergo facial vein reconstruction immediately after neck dissection\n3. Visit the clinic once every 3 months for routine checkups and tests. This is typical for most patients treated for head and neck cancer including those not enrolled in the trial.\n4. Fill out short questionnaires to help understand quality of life after head and neck cancer treatment\n5. Undergo lymphography in the OR and at the 1-year mark in the office. This is a simple test performed without radiation exposure. It requires 3 very small skin injections to perform the test.",[27],"Head and Neck Cancer",[29,30,31],"head and neck cancer","head and neck lymphedema","lymphedema","NOT_YET_RECRUITING","2026-08-18",{"date":35,"type":36},"2026-08-19","ACTUAL",{"date":38,"type":21},"2026-09",{"date":40,"type":21},"2028-12",{"name":42,"class":43},"University of Pittsburgh","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100556513","cognitive-training-as-an-adjunct-to-ketamine-in-real-world-clinics-100556513","NCT06526078","Cognitive Training as an Adjunct to Ketamine in Real-world Clinics","A Brief Automated Neurocognitive Training to Enhance the Real-World Impact of Ketamine's Rapid Antidepressant Effect","Inclusion Criteria:\n\n1. be between the ages of 18 and 80 years\n2. score ≥20 on the Montgomery-Asberg Depression Rating Scale (MADRS)\n3. per SCID-5-RV interview, meet DSM-5 diagnostic criteria for at least one of the following: Major Depressive Disorder, Bipolar Disorder (I or II), Persistent Depressive Disorder, or Other Specified Depressive or Bipolar Disorder\n4. exhibit treatment resistance, defined as: (a) failure to respond to ≥1 adequate trials of an evidence-based treatment for mood disorder \\[per the Antidepressant Treatment History Form-Short Form Modified Score Sheet (ATHF-SF-Modified)\\] and\u002For (b) failure to respond to ≥1 adequate mood stabilizer or other evidence-based treatment trials (for bipolar depression patients) and\u002For (c) a history of intolerance during attempted trials of evidence-based treatments for mood disorders and\u002For (d) failure to respond to ≥1 prior treatment trials (e.g., medication, psychotherapy) for Post Traumatic Stress Disorder (PTSD)\n5. be eligible and clinically enrolled for an upcoming ketamine or esketamine induction series at one of our study clinics according to that clinic's standard intake procedures\n6. agree to maintain a stable schedule of concomitant psychiatric medications throughout the ketamine induction phase (minor adjustments to PRN meds and timing of meds are allowable), and for 4 weeks post-induction phase\n7. possess a level of judgment and understanding sufficient to agree to all procedures required by the protocol and must sign an informed consent document\n8. be willing and able to provide names and contact information for at least 1 additional emergency contact in the patient's proximal geographic area (in addition to the ketamine treatment team at the enrolling site)\n\nExclusion Criteria:\n\n1. Presence of current\u002Facute psychosis, mania, or dementia, or a diagnosis of developmental disorder with significant language and\u002For intellectual impairment (e.g., autism spectrum disorder)\n2. Current\u002Facute suicide risk with intent to act, defined as CSSRS past-week ideation score ≥ 4 among outpatients; patients engaged in residential or inpatient care at the time of enrollment need not meet this CSSRS score criterion, as their current\u002Facute suicide risk is extremely low by virtue of the residential\u002Finpatient, round-the-clock care they are already receiving at time of enrollment\n3. Concern for dementia or significant cognitive decline, per interviewer observations and impressions during screening assessments\n4. Current pregnancy\n5. English reading level \\\u003C5th grade as per patient self-report Rationale: to ensure adequate reading comprehension for verbal ASAT\u002Fsham stimuli which are presented in English","80 Years",{"count":54,"type":21},600,[24],"In a sample of patients already receiving ketamine (or esketamine) treatment as part of their clinical care, this project seeks to test whether we can enhance and\u002For extend (es)ketamine's rapid effects by introducing helpful information delivered by a computer-based cognitive training protocol. This work could ultimately lead to the ability to treat depression more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.",[58],"Depression","RECRUITING",{"date":35,"type":36},{"date":62,"type":36},"2024-11-12",{"date":64,"type":21},"2029-05-31",{"name":42,"class":43},3,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":44},"100648808","effect-of-fpp-on-cutaneous-barrier-integrity-100648808","NCT07725835","Effect of FPP on Cutaneous Barrier Integrity","Pilot Study of Fermented Papaya Preparation (FPP) Impact on Transepidermal Water Loss of Skin on Face, Arms, and Hands","FPP OSATO","Inclusion Criteria:\n\n1. 50-75 years\n2. Willing to allow collection of 3 blood samples (Baseline, Week 12 and Week 20)\n3. Willing to log daily compliance with FPP intake during the study period (12 weeks)\n4. Absence of active systemic disease per investigator judgement.\n5. No current use of immunosuppressant or immunomodulatory medications.\n6. No active dermatological conditions at measurement sites that could impair measure, per investigator judgement.\n7. Investigator determination of general good health.\n\nExclusion Criteria:\n\n1. Co-morbidity or concurrent medication that the Investigator deems impactful to patient safety or ability to adhere to FPP dosage.\n2. Co-morbidity or concurrent medication that the Investigator deems confounding to outcome measure (i.e., topical or systemic steroid).\n3. Current or history of allergy to FPP ingredients: Dextrose, Carica papaya, or Food yeast.\n4. Concurrent participation in another interventional trial that may impact measures, per investigator judgement.\n5. Uncontrolled diabetes (A1c \\>7%).\n6. Open wounds or actively receiving Wound Care services.\n7. Pregnant or breastfeeding women.\n8. Current use of warfarin.",true,"50 Years","75 Years",{"count":79,"type":21},30,[24],"This pilot study will test how Fermented Papaya Preparation (FPP) impacts overall TEWL of areas that commonly display diminished barrier function, such as the skin from face, arms, and hands. Areas of diminished barrier function are defined as those not visible to the eye but identified as areas of high transepidermal water loss (TEWL) as measured by a non-invasive pen-like device. A TEWL value of 20 or higher at a location would be considered high TEWL. Participants will attend 5 visits over 20 weeks, with 12-weeks of FPP treatment, and 8-weeks of follow-up.",[83,84],"Skin Barrier Dysfunction","Healthy Volunteers","2026-08-17",{"date":35,"type":36},{"date":38,"type":21},{"date":89,"type":21},"2028-07",{"name":42,"class":43},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":17,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":44},"100545755","the-power-down-pilot-study-a-novel-bedtime-manipulation-protocol-100545755","NCT06386029","The Power Down Pilot Study: A Novel Bedtime Manipulation Protocol","Powering Down: A Pilot Study of a Bedtime Manipulation to Support Sleep for Autistic Children","Inclusion Criteria:\n\n1. Child between the ages of 6 and 10 years old (at least 40%, no more than 60% female)\n2. Parent-reported autism diagnosis for child\n3. Parent-reported extended and problematic settling down delay\n4. Parent-reported sensory over-responsivity (a \"yes\" to at least 8 items in the sensory screening section of the checklist)\n5. Parent willing to participate in nightly routine during the 2 week study\n6. Located within the Pittsburgh area\n\nExclusion Criteria:\n\n1. Participants will be excluded if they do not understand English or are unable to travel to University of Pittsburgh Medical Center Western Psychiatric Hospital.\n2. Children who have trauma or other histories for whom physical touch is triggering (per caregiver report) will be excluded.\n3. If a child spends bedtime at a different caregiver's home for \\>50% of the nights and that caregiver is not willing to participate in this study, the child will be excluded from this study.","6 Years","10 Years",{"count":101,"type":21},10,[24],"The goal of this pilot intervention study is to examine the feasibility and acceptability of a novel bedtime manipulation protocol called \"The Power Down\" for autistic youth, ages 6-10. The main questions it aims to answer are:\n\n1. Is the Power Down feasible for caregivers to do each night?\n2. Do the families find the Power Down an acceptable intervention to address their child's difficulties settling down to fall asleep?",[105,106],"Autism","Sleep Disturbance",[108,109,110],"Sleep disturbances","Emotion Dysregulation","Sensory Processing","2026-08-12",{"date":113,"type":36},"2026-08-14",{"date":115,"type":36},"2025-07-05",{"date":117,"type":21},"2026-12",{"name":42,"class":43},{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":44},"100477875","relationship-of-inflammation-and-pulmonary-function-to-fungal-translocation-in-hiv-100477875","NCT05502653","Relationship of Inflammation and Pulmonary Function to Fungal Translocation in HIV","Relationship of Fungal Translocation, Inflammation, and Pulmonary Function in HIV","RIFFT","Inclusion Criteria:\n\n* Age 18 to 80\n* HIV positive\n* Virally-suppressed on ART for at least 6 months\n* subjects enrolled in Dr. Morris's HLRC Studies STUDY20020151, STUDY19080258, STUDY19060243, STUDY19070181, STUDY19070181, STUDY19050326 OR subjects being seen at the HIV\u002FPACT clinics.\n\nExclusion Criteria:\n\n* Contraindication to pulmonary function testing (i.e., abdominal or cataract surgery within 3 months, recent myocardial infarction, etc.).\n* individuals with clinical or radiographic evidence of another significant pulmonary diagnosis (e.g. interstitial lung disease, active asthma)\n* inflammatory bowel disease\n* pregnancy\n* use of antibiotics in the prior 2 weeks\n* immunomodulators in the prior 6 months\n* unable to perform any study procedures.",{"count":128,"type":21},100,"OBSERVATIONAL","The investigator will study the origin of fungal translocation in HIV, its relationship to the mycobiome, and its relationship to lung function and inflammation. Supported by the preliminary data and published studies, this project is based on the premise that circulating BDG derived from microbial translocation stimulates inflammation and worsens lung function in PWH.\n\nChronic obstructive pulmonary disease (COPD) is a significant public health problem with few therapies that modify disease trajectory. COPD is a leading cause of mortality in the United States associated with increased morbidity and healthcare costs. Long-acting bronchodilators and inhaled corticosteroids are mainstays of therapy that control symptoms and reduce acute exacerbation frequency, but do not have a significant impact on mortality or lung function trajectory. The National Heart, Lung, and Blood Institute's COPD National Action Plan focuses on the critical need for research to characterize COPD risk factors and disease mechanisms in order to improve the understanding of causes and progression of disease. The ultimate goal is to provide precision therapy to appropriate patient subgroups to preserve health or arrest disease progression.\n\nMicrobial organisms in the gut may have a profound effect on lung disease. The role of the gut-lung axis, defined as the cross-talk between gut microbiota and the lungs, in the pathogenesis of chronic respiratory diseases is emerging as an area of interest. Perturbations of gut microbiota characterized by low microbial diversity and changes in microbiota abundance are linked to childhood asthma risk, airflow obstruction in adult asthma, and severe lung dysfunction in cystic fibrosis. Studies in animals show that both a high fiber diet that modulates gut microbiota and an abundance of beneficial bacterial strains attenuate inflammation, emphysema, and COPD development in response to cigarette smoke exposure in murine models. In humans, recent investigations show differences in the gut microbial communities between COPD patients and healthy individuals as well as shifts in the gut microbiome with acute exacerbations of COPD.",[132,133,134],"HIV Infections","Inflammation","COPD",{"date":113,"type":36},{"date":137,"type":36},"2022-09-01",{"date":139,"type":21},"2027-11-01",{"name":42,"class":43},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":75,"sex":17,"minAge":18,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":44},"100458941","cortical-excitability-in-cyclic-vomiting-syndrome-100458941","NCT05256160","Cortical Excitability in Cyclic Vomiting Syndrome","Inclusion Criteria:\n\n* diagnosis of CVS\n\nExclusion Criteria:\n\n* history of CVS (for healthy control population only)\n* psychosis or altered cognitive status\n* history of head injury, metal in the skull, stroke, or a history of seizures or a history of syncope (fainting or passing out)\n* implantable devices, such as a pacemaker or nerve stimulator\n* current use of the following medications or use of substances which are known to lower the seizure threshold: clozapine (Clozaril), chlorpromazine (Thorazine), amphetamines or methamphetamine, Ecstasy, Ketamine, Angel Dust\u002FPCP, cocaine, or 3 or more alcoholic drinks per day\n* pregnancy","60 Years",{"count":149,"type":21},110,[24],"This exploratory study will determine if there are differences in cortical excitability between patients suffering from cyclic vomiting syndrome (CVS) and healthy control subjects, as assessed by a non-invasive method of brain stimulation (Transcranial Magnetic Stimulation, TMS).",[153],"Cyclic Vomiting Syndrome",{"date":113,"type":36},{"date":156,"type":36},"2022-05-16",{"date":158,"type":21},"2027-06",{"name":42,"class":43},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100436801","phase-3-clarifying-the-optimal-application-of-slt-therapy-trial-100436801","NCT04967989","Clarifying the Optimal Application of SLT Therapy Trial","COAST","Inclusion Criteria:\n\n1. Age 18 or older and in good health\n2. Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):\n\n   1. High-risk ocular hypertension (OHT): IOP \\> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \\>0.2 between eyes)\n   2. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° \\\u003C15 dB (see figure on next page)\n   3. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points \\\u003C15 dB or mean deviation -12.0 dB or better with 1 central 5° points \\\u003C15 dB (see figure on next page).\n3. Each eye with BCVA 20\u002F200 (UK 6\u002F60) or better\n\nExclusion Criteria:\n\n1. Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment)\n2. Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure\n3. Advanced POAG in either eye (worse than moderate POAG as defined above)\n4. Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye\n5. Mean IOP \\> 35 mmHg at either the screening or baseline visit in either eye\n6. Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye\n7. Contraindications to SLT or any other study intervention\n8. Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye\n9. Any intraocular surgical procedure within the past 6 months in either eye\n10. Inability to attend all scheduled study visits\n11. Pregnant or planning to become pregnant in the next 4 years",{"count":168,"type":21},790,[170],"PHASE3","The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.",[173],"Glaucoma and Ocular Hypertension",[175,176,177],"glaucoma","selective laser trabeculoplasty","clinical trial",{"date":113,"type":36},{"date":180,"type":36},"2021-09-07",{"date":182,"type":21},"2027-08-31",{"name":42,"class":43},29,{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":194,"studyType":129,"phases":4,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":44},"100381202","inflammatory-bowel-disease-ibd-research-registry-100381202","NCT04243525","Inflammatory Bowel Disease (IBD) Research Registry","University of Pittsburgh Medical Center (UPMC) Center for Inflammatory Bowel Disease (IBD) Research Registry","Inclusion Criteria:\n\nAll patients age 18 and above seeking medical care at the Center for Inflammatory Bowel Diseases Clinic at UPMC\n\nExclusion Criteria:\n\nN\u002FA",{"count":193,"type":21},5000,"20 Years","Patients seen at the Center for Inflammatory Bowel Disease will be asked to provide their written informed consent (authorization) to allow their identifiable medical record information related to their Inflammatory Bowel Disease to be placed in Center's Research Registry for the purpose of facilitating retrospective research studies directed at Inflammatory Bowel Disease, and the identification and recruitment of potential, eligible subjects for participation in future research studies involving Inflammatory Bowel Disease.\n\nInformation obtained from the Inflammatory Bowel Disease Registry will allow a better classification of disease and factors that influence the natural course of disease; which may lead to a better understanding of the pathogenesis of IBD and may permit the development of better therapies and the potential for preventive therapies.",[197],"Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","2026-08-11",{"date":111,"type":36},{"date":201,"type":36},"2009-05",{"date":203,"type":21},"2030-05",{"name":42,"class":43},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":212,"minAge":213,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":44},"100651444","addressing-nocturia-in-older-women-utilizing-behavioral-sleep-intervention-and-brief-mindfulness-100651444","NCT07760779","Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness","ANOWSM","Inclusion Criteria:\n\n* Female\n* Age \\> or =65 years\n* Nocturia ≥2\u002Fnight\n* Poor sleep (Insomnia Severity Index ≥8)\n* MoCA (including trail making) \\>26\n\nExclusion Criteria:\n\n* Conditions that affect bladder function: Multiple sclerosis, Alzheimer's disease, spinal cord injury, urethral obstruction, urinary retention, interstitial cystitis, bladder cancer, radiation to the pelvic area, bladder surgery, current or uncontrolled chronic or recurrent bowel issues, bacterial endocarditis\n* cardiac or respiratory disease that limits daily function\n* Unstable or acute medical condition:\n\n  \\- Any acute medical condition that requires immediate treatment such that it would interfere with the study protocol; Each instance will be assessed on a case-by-case basis by our study physician who may postpone a participant's enrollment; stably managed chronic conditions are exempt from this exclusion.\n* Untreated, current, severe psychiatric condition (assessed during Visit 1a- medical history)\n* Post void residual ≥ 200ml- assessed during baseline visit\n* Currently diagnosed and\u002For untreated obstructive sleep apnea, untreated restless leg syndrome, untreated parasomnia\n* Untreated or poorly controlled fluid overload conditions like CHF, diabetes","FEMALE","65 Years",{"count":215,"type":21},80,[24],"The goal of this clinical trial is to examine and compare the effect of behavioral sleep treatment: BBTI (brief behavioral treatment of insomnia) and brief mindfulness (MI), independently and combined vs control on frequency of nighttime awakenings to void (nocturia) and on nighttime urine production in older women over the age 65 years with nocturia.\n\nTo study the effect of these treatments, participants will be randomly assigned to one of the following groups 1) BBTI alone, 2) MI alone, 3) BBTI+MI, or 4) control: sleep information only without any structured sleep or mindfulness therapy.\n\nThe study aims to examine the effect of these therapies at end-of-treatment (week 4), as well sustained effects at 3- and 6-months. The main questions the study aims to answer are:\n\n1. do these treatments reduce the frequency of nighttime awakenings to void\n2. do these treatments reduce the volume of nighttime urine production\n3. do these treatments improve sleep quality\n\nFrequency of nocturia and sleep quality will be assessed via questionnaires and nighttime urine volume using bladder-sleep diaries which is 3-day record participants will complete at home documenting every time they go to the bathroom and volume they voided. In addition, sleep and sleep interruptions will also be assessed using an FDA-cleared home sleep testing device called Zmachine®.",[219,220],"Nocturia","Insomnia","2026-08-07",{"date":111,"type":36},{"date":224,"type":21},"2026-09-15",{"date":226,"type":21},"2029-04-30",{"name":42,"class":43},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":75,"sex":212,"minAge":77,"maxAge":4,"enrollmentInfo":234,"targetDuration":236,"studyType":129,"phases":4,"briefSummary":237,"conditions":238,"keywords":241,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":250,"locationsCount":44},"100639606","automated-iadl-sensing-to-refine-measurement-of-older-adult-daily-activity-100639606","NCT07585864","Automated IADL Sensing to Refine Measurement of Older Adult Daily Activity","Inclusion Criteria:\n\n1. Participant in University of Pittsburgh Pepper Center research registry\n2. Age 75+\n3. Female\n4. Residing in community\n5. Meets criteria for normal cognition or mild cognitive impairment on telephone screening (Memory Impairment Screen \\>= 5)\n6. Daily, independent performance of cooking and light cleaning tasks\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Meets criteria for possible dementia (Memory Impairment Screen \\\u003C= 4)\n3. Reports difficulty with activities of daily living (dressing, feeding oneself, using toilet, bathing)\n4. Uses mobility assistance device for indoor ambulation\n5. Medical conditions that may interfere with participation (e.g., severe untreated psychiatric disorders, unstable cardiovascular conditions, Parkinson's disease)\n6. Current participation in other interventional studies or clinical trials.",{"count":235,"type":21},20,"1 Day","The instrumental activities of daily living (IADL) refer to complex daily activities required for adult independence, such as preparing a meal or taking medications. This study will assess the efficacy of sensing technologies (smartwatch, computer vision, eye tracking) for recognizing IADL activities in naturalistic settings and score performance relative to ratings from occupational therapists. If successful in assessing the efficiency of IADL, the sensing technologies will be a valuable addition to geriatric assessment.",[239,240],"Cognitive Ability General","Functional Abilities",[242,243,244,245],"Occupational therapy","machine learning","accelerometry","computer vision",{"date":198,"type":36},{"date":248,"type":36},"2026-07-30",{"date":158,"type":21},{"name":42,"class":43},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":75,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":268,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":44},"100651459","neurocomputational-dynamics-of-cooperation-100651459","NCT07759973","Neurocomputational Dynamics of Cooperation","COBRA","Online cohort inclusion criteria:\n\n* English fluency\n* US residency\n* Owner of a desktop or laptop computer\n* Adult aged 18-100\n\nOnline cohort exclusion criteria:\n\n* Participants who have participated in an earlier version of the study\n* Inability to consent\n* Self-reported history of neurological disorder or brain damage\n* Self-endorsed history of psychosis or mania\n\nClinical cohort inclusion criteria:\n\n* Adult aged 20-60 years old\n* English fluency\n* Owner of a smartphone with celluar data\n\nClinical cohort exclusion criteria:\n\n* Inability to consent\n* Self-reported history of neurological disorder or brain damage\n* Clinician-rated psychosis or mania in the last 6 months\n* Current intoxication or withdrawal\n* Estimated IQ \\\u003C 70\n* fMRI safety concerns\n* Pregnancy\n* Lack of stable psychiatric treatment (e.g., medication dosage, therapy modality) for the previous two months\n\nInformant inclusion criteria:\n\n* Adult aged 18+ years old\n* English fluency\n* Owner of a smartphone with celluar data\n* Must have 4+ interactions\u002Fweek with the participant for at least 6 months prior to study baseline\n\nInformant exclusion criteria:\n\n\\- Lack of a smartphone with cellular data at study baseline","100 Years",{"count":260,"type":21},1612,[24],"The purpose of this study is to understand brain function, how people make decisions when they interact with others, and how brain function and behavior relate to personality traits.",[264,265,266,267],"Social Cognition","Personality Disorder","Mental Health","Interpersonal Conflict",[266,269,270,271,272,273,274,275,276],"Multi-informant EMA","Neuroimaging","fMRI","Informant","Multi-method","Ecological Momentary Assessment","Self-report","Longitudinal","2026-08-06",{"date":111,"type":36},{"date":280,"type":21},"2026-09-01",{"date":282,"type":21},"2031-06-30",{"name":42,"class":43},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":303,"leadSponsor":304,"locationsCount":44},"100651309","promote-a-pilot-and-feasibility-study-100651309","NCT07758439","PROMOTE: A Pilot and Feasibility Study","PeRsOnalized MethOdone TrEatment (PROMOTE) by Implementing Shared Decision-making: A Pilot and Feasibility Study","PROMOTE","Inclusion Criteria:\n\nCLIENT INCLUSION CRITERIA\n\n* Age ≥18 years old\n* Receiving methadone treatment (i.e., self-report of ingestion of at least one administered or dispensed dose of methadone in past 7 days) at the pilot OTP\n* Able and willing to provide informed consent\n* Able to read and write in English or Spanish\n\nHEALTHCARE PROFESSIONAL INCLUSION CRITERIA\n\n* ≥18 years old\n* Partners with clients to make methadone treatment decisions (e.g., peer navigator, physician, advanced practice provider, nurse, counselor)\n* Able and willing to provide informed consent\n* Able to read and write in English\n\nCLIENT EHR INCLUSION CRITERIA\n\n* ≥18 years old\n* Documented receipt of at least one dose of methadone treatment (i.e., administrated or dispensed) from the participating OTP during a 6-month study period\n\nSEMI-STRUCTURED INTERVIEW INCLUSION CRITERIA\n\n* Clients and healthcare professionals eligible as described above may be included in semi-structured interviews. We will also include the OTP organizational leadership (e.g., clinic director, medical director, regional director). The investigators will purposively sample clients, healthcare professionals, and OTP leadership to contrast positional differences in experiences of SDM and its implementation. The investigators may modify this sampling approach based on preliminary results and advisory board feedback.\n\nExclusion Criteria:\n\nCLIENT EXCLUSION CRITERIA\n\n* Do not meet client inclusion criteria\n* For the client survey, each client may complete the survey only once during the 6-month implementation period.\n\nHEALTHCARE PROFESSIONAL EXCLUSION CRITERIA\n\n* The investigators will exclude healthcare professionals who do not meet inclusion criteria\n\nCLIENT EHR EXCLUSION CRITERIA\n\n* The investigators will exclude clients who do not meet inclusion criteria\n\nSEMI-STRUCTURED INTERVIEW EXCLUSION CRITERIA\n\n* The investigators will exclude clients or healthcare professionals who do not meet inclusion criteria.",{"count":293,"type":21},58,"To assess the feasibility and acceptability of implementing and evaluating shared decision making (SDM) within a single opioid treatment program (OTP) using Implementation Facilitation (IF), and to obtain pilot data on key implementation and effectiveness outcomes to inform a future full-scale hybrid type 3 implementation-effectiveness trial.",[296],"Shared Decision Making",[298,299,300],"shared decision making","opioid treatment program","implementation facilitation",{"date":198,"type":36},{"date":38,"type":21},{"date":158,"type":21},{"name":42,"class":43},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":75,"sex":17,"minAge":312,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":320,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":44},"100648114","caregiver-adolescent-dating-violence-prevention-intervention-pilot-trial-100648114","NCT07718022","Caregiver-Adolescent Dating Violence Prevention Intervention Pilot Trial","Relationship Abuse Prevention Intervention Implemented With Sexual and Gender Diverse Youth and Their Caregivers - Pilot Trial","Inclusion Criteria:\n\n* SGDY eligibility includes:\n\n  1. ages 14 to 18\n  2. identifies as sexually or gender diverse (e.g., gay, lesbian, bisexual, queer, transgender, or nonbinary)\n  3. uses English\n  4. willing to travel to Pittsburgh for 1 in-person event; and\n  5. can identify a caregiver who can also participate.\n\nCaregivers eligibility includes:\n\n1. age 18 or older;\n2. a caregiver of an SGDY ages 14 to 18;\n3. uses English;\n4. willing to travel to Pittsburgh for 1 in-person event; and\n5. has a child participating in this study. Caregivers can include parents or any other person whom the adolescent identifies as a trusted adult in their life. We will only enroll 1 caregiver for each SGDY; because this is a dyadic study each adolescent needs a matched participating caregiver and vice versa.\n\nExclusion Criteria:\n\n* Does not meet eligibility criteria\n* Incarcerated during the study\n* Unable to provide verbal or REDCap consent or assent","14 Years",{"count":314,"type":21},108,[24],"This is a pilot clinical trial to test an intervention called FLARE, which is an adolescent relationship abuse prevention program for sexual and gender diverse youth and their trusted adults. FLARE comprises in-person, virtual, and asynchronous programming developed by and for caregivers and adolescents.",[318,319],"Adolescent Relationship Abuse","Sexual and Gender Minorities",[321,322,323,324],"adolescent relationship abuse","parental monitoring","intervention","sexual and gender diverse youth",{"date":326,"type":36},"2026-08-10",{"date":328,"type":36},"2026-08-01",{"date":330,"type":21},"2028-07-01",{"name":42,"class":43},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":349,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":44},"100621657","an-evaluation-of-the-impact-of-pharmacist-comprehensive-medication-management-with-pharmacogenomic-results-to-improve-depression-outcomes-in-community-pharmacies-100621657","NCT07373470","An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.","Genotype-guided Comprehensive Medication Management to Improve Depression Outcomes in Pennsylvania","COMPASS-PGx","INCLUSION CRITERIA:\n\n* At targeted community pharmacy for:\n\n  * New prescription or change in dose\u002Fschedule of SSRI (citalopram, escitalopram, sertraline, paroxetine), OR\n  * Concurrent SSRI (citalopram, escitalopram, sertraline, paroxetine) and new prescription\u002Fchange in SNRI (desvenlafaxine, duloxetine, and venlafaxine) \u002F bupropion.\n* Depressive symptoms confirmed by PHQ8 assessment (\\>5 indicating at least mild depressive symptoms)\n* UPMC patient (or able\u002Fwilling to become one) and has UPMC provider (or able\u002Fwilling to obtain one)\n* Signed consent to join Pitt+Me Discovery biobanking research study.\n* English-speaking\n\nEXCLUSION CRITERIA:\n\n* Inability to receive CMM at specific pharmacy\u002Fpharmacist\n* Comorbid diagnosis of schizophrenia (patient-reported)\n* Untreated sleep disorder (patient-reported)\n* Pitt+Me Discovery participant who has elected to not receive return of results, or who has already received results previously",{"count":341,"type":21},220,[24],"The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes.\n\nThe primary aim is to determine whether comprehensive medication management with review of PGx testing results improves depression symptoms, compared with usual care.\n\nParticipants 18 years of age or older who have undergone PGx testing (e.g. through an independent biobanking study (Pitt+Me Discovery) who require initiation or adjustment of antidepressant therapy will be randomly assigned to receive either PGx-guided comprehensive medication management or usual care. Those who receive usual care will receive their PGx results at the end of the study. Researchers will compare the groups to assess whether PGx-guided care provided in partnership with community pharmacists and prescribers results in better depression and medication outcomes.",[345,346,347,348],"Pharmacogenetics","Depression - Major Depressive Disorder","Pharmacogenomic Drug Interaction","Community Pharmacy Services",[350,351,352,353,354,355,356,357,358,359],"precision medicine","pharmacogenomics","PGx","Comprehensive medication management","pharmacist","community pharmacy","medication review","antidepressants","pharmacogenomic testing","management of depression",{"date":221,"type":36},{"date":362,"type":21},"2026-08",{"date":364,"type":21},"2026-12-31",{"name":42,"class":43},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":44},"100607051","hybrid-type-i-effectiveness-implementation-cluster-randomized-controlled-trial-of-cares-100607051","NCT07183527","Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES","Hybrid Type I Effectiveness-Implementation Cluster Randomized Trial of CARES","CARES","Inclusion Criteria:\n\n* Diagnosis of Cancer\n* Age 18 years or older\n* Read and write in English\n\nExclusion Criteria:\n\n* Evidence of thought disorder\n* Evidence of delusions\n* Evidence of hallucinations\n* Evidence of suicidal ideation with a plan",{"count":375,"type":21},1750,[24],"The trial will examine the effectiveness and facilitators and barriers of implementation of CARES, an integrated screening and stepped collaborative care intervention",[372,379],"Standard of Care",[381,382,383,384,385,386],"implementation","stepped collaborative care","integrated screening and treatment","cluster randomized controlled trial","cancer","screening","2026-08-05",{"date":326,"type":36},{"date":390,"type":36},"2025-08-08",{"date":392,"type":21},"2030-01-31",{"name":42,"class":43},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":401,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":405,"conditions":406,"keywords":413,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":44},"100359417","molecular-basis-of-pediatric-liver-cancer-100359417","NCT03959800","Molecular Basis of Pediatric Liver Cancer","Genetic and Molecular Basis of Pediatric Liver Cancer","Inclusion Criteria:\n\n* Prior or current treatment for a childhood liver tumor, malignant or benign, at age \\\u003C21 years.\n* Biological parents and siblings of eligible children.\n\nExclusion Criteria:\n\n* No prior or current treatment for a childhood liver tumor.\n* Non-biological parents, legal guardians, or non-biological siblings of eligible children.","0 Years","99 Years",{"count":404,"type":21},1600,"The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.",[407,408,409,410,411,412],"Childhood Liver Cancer","Liver Malignant Tumors","Embryonal Sarcoma of Liver (Disorder)","Hepatoblastoma","Hepatocellular Carcinoma","Rhabdoid Tumor of Liver",[410,411,414],"Pediatric Liver Cancer",{"date":326,"type":36},{"date":417,"type":36},"2015-06-22",{"date":419,"type":21},"2035-06-30",{"name":42,"class":43},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":44},"100306732","mapping-disease-pathways-for-biliary-atresia-100306732","NCT03273049","Mapping Disease Pathways for Biliary Atresia","Coordinating Center- Mapping Disease Pathways for Biliary Atresia","BA","Inclusion Criteria:\n\n* living individuals who were diagnosed with Biliary Atresia and received or are about to receive a liver transplant from multiple participating centers (Children's Hospital of Pittsburgh, Kings College Hospital, Children's Hospital of Birmingham, and Hospital Sírio-Libanês).\n\nExclusion Criteria:\n\n* No child participant in the care of the state will be enrolled, nor will patients in the care of temporary or informal guardians be enrolled",{"count":430,"type":21},1100,"This project will primarily evaluate the developmental\u002Fgenetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.",[433],"Biliary Atresia",{"date":326,"type":36},{"date":436,"type":36},"2016-07-21",{"date":438,"type":21},"2035-07-21",{"name":42,"class":43},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":449,"conditions":450,"keywords":453,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":44},"100145373","biomarkers-in-transplant-recipients-to-improve-outcomes-100145373","NCT01163578","Biomarkers in Transplant Recipients to Improve Outcomes","Study of Biomarkers in Solid Organ and Bone Marrow Transplant Recipients to Better Treat Rejection","Inclusion Criteria:\n\n* Recipients of abdominal, thoracic and bone marrow allografts that are receiving inpatient and outpatient follow-up with routine laboratory tests at the University of Pittsburgh Medical Center.\n* All Ages\n* Subject or parents are able to read and understand the informed consent\n\nExclusion Criteria:\n\n* Subjects and\u002For their parents who are unable to read and understand informed consent.",{"count":448,"type":21},1200,"The objective of this study is to evaluate whether certain proteins, expressed in biological tissues can indict a better understanding of the effect of drugs that are used to treat rejection, and of processes leading to rejection and rejection-free outcomes.",[451,452],"Solid Organ Transplantation","Bone Marrow Transplantation",[454,455],"Transplantation","Rejection",{"date":326,"type":36},{"date":458,"type":4},"2005-03",{"date":460,"type":21},"2030-03",{"name":42,"class":43},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":75,"sex":17,"minAge":18,"maxAge":213,"enrollmentInfo":469,"targetDuration":4,"studyType":22,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":44},"100609602","evaluating-the-effectiveness-of-the-health-app-recommendation-tool-100609602","NCT07216716","Evaluating the Effectiveness of the Health App Recommendation Tool","HART","Inclusion Criteria:\n\n* Aged between 18 and 65\n* Serving as an active caregiver for a loved one with Alzheimer's disease or a related dementia\n* Have access to smart devices such as smartphones, tablets, or smartwatches\n\nExclusion Criteria:\n\n* Individuals with Alzheimer's disease or a related dementia, or with severe cognitive decline, will be excluded\n* Participants who do not provide caregiving on a routine basis (e.g., part-time or secondary caregivers) will be excluded\n* Participants who do not own or have access to any smart device will be excluded",{"count":470,"type":21},15,[24],"This study aims to assess the effectiveness of the Health App Recommendation Tool (HART), an evidence-based tool that evaluates app features and matches them to the needs, abilities, and preferences of individuals with Alzheimer's disease and related dementias (ADRD) or their caregivers. This novel tool is not an app in and of itself, but rather an assessment tool used to determine how well suited a given app is for a member of the ADRD or caregiver population.\n\nSpecifically, the objective of this research is to assess the acceptability of the current HART design among target end-users in their individual contexts. The overarching goal of this project is to connect those in the ADRD community with available, usable, and effective digital tools to promote the highest possible level of health and wellness in community settings.\n\nTo achieve this goal, the study will recruit 15 family caregivers living with their loved ones with ADRD, who will trial HART and provide feedback. Participation will include two data collection sessions (pre-intervention and post-intervention) within a four-week trial period. Participants will be asked to complete the HART, explore the recommended apps, and provide feedback on HART's usability through several brief surveys.",[474],"Alzheimers Disease Related Dementias",[476,477,478,479,480],"Alzheimer's Disease","Dementia","Dementia Caregivers","Smart Technology","Assistive Technology","2026-08-04",{"date":277,"type":36},{"date":484,"type":36},"2025-12-05",{"date":486,"type":21},"2026-11-30",{"name":42,"class":43},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":497,"briefSummary":498,"conditions":499,"keywords":503,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":44},"100593119","the-effect-of-specialty-care-on-recovery-from-cardiac-arrest-trial-the-sparc-trial-100593119","NCT07002294","The Effect of SPecialty cAre on Recovery From Cardiac Arrest Trial (the SPARC Trial)","SPARC","Inclusion Criteria:\n\n* Out-of-hospital cardiac arrest\n* Resuscitated from cardiac arrest with palpable pulse in the emergency department\n* Treated at one of participating hospital emergency departments\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Known prior advanced directives or decision to limit critical care\n* Known pre-arrest dependent functional status (e.g., living in a skilled nursing facility, hospice or bedbound)\n* Arrest in the emergency department \\>4 hours after arrival\n* Traumatic etiology of arrest\n* Known to have opted-out from the SPARC trial",{"count":496,"type":21},1618,[24],"This randomized clinical trial will determine if adult participants who are in the emergency department after being resuscitated from a cardiac arrest outside of the hospital benefit from care delivered at specialized centers.\n\nThe main question that it will answer is whether transferring participants to a hospital with a specialized cardiac arrest service improves recovery of function after 90 days.\n\nParticipants will receive all usual medical care, but some participants will be offered transfer to a regional cardiac arrest center and others will be offered care at the closest appropriate hospital. Investigators will interview participants after 90 days to assess their recovery.",[500,501,502],"Cardiac Arrest (CA)","Heart Arrest","Heart Arrest, Out-Of-Hospital",[504],"cardiac arrest",{"date":277,"type":36},{"date":507,"type":36},"2026-05-11",{"date":509,"type":21},"2032-01",{"name":42,"class":43},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":522,"conditions":523,"keywords":527,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":44},"100614524","investigating-real-time-immunotherapy-symptoms-study-100614524","NCT07280715","Investigating Real-Time Immunotherapy Symptoms Study","Digital Remote Patient Monitoring and Triage During Cancer Immunotherapy","IRIS","Inclusion Criteria:\n\n* receiving immune checkpoint inhibitor therapy at UPMC Hillman Cancer Center for melanoma;\n* age 18 years or older;\n* ability to read and write in English;\n* owns and uses a smartphone capable of running study applications\n\nExclusion Criteria:\n\n* under 18 years old; and\n* unable to read and write in English",{"count":520,"type":21},40,[24],"The goal of this study is to evaluate the feasibility of using information from wearable devices and self-reported symptoms to remotely monitor patients during immunotherapy. The main questions it aims to answer are:\n\n* Is the digital remote patient monitoring tool feasible and acceptable to patients?\n* Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment?\n\nParticipants will:\n\n* Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study.\n* As feasible: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).\n\nIf participant is randomly assigned to the intervention group, they will also:\n\n* Complete weekly symptom ratings via digital remote patient monitoring tool\n* Wear a Fitbit activity tracker as feasible for 90 days.\n* At the end of the study, complete a semi-structured interview to provide feedback on the study.",[524,525,526],"Cancer","Melanoma (Skin Cancer)","Immunotherapy",[528,529],"quality of life","adverse events","2026-07-31",{"date":481,"type":36},{"date":533,"type":36},"2026-06-17",{"date":364,"type":21},{"name":42,"class":43},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":212,"minAge":18,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":22,"phases":545,"briefSummary":546,"conditions":547,"keywords":551,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":44},"100643173","mobile-health-program-for-post-preeclampsia-hypertension-100643173","NCT07599579","Mobile Health Program for Post-Preeclampsia Hypertension","Multilevel Mobile Health Program to Improve Hypertension Among Midlife Women After Hypertensive Disorder of Pregnancy","Inclusion Criteria:\n\n* Women who had a history of HDP (either gestational HTN or preeclampsia) diagnosed by ACOG guidelines at the time of delivery at Magee-Womens Hospital between 2008 and 2015, thus 10 to 20 years from their index pregnancy complicated by HDP.\n* Evidence of current stage 2 HTN (BP ≥ 140\u002F90 mmHg with or without treatment with antihypertensive medication).\n\nExclusion Criteria:\n\n* Known clinical CVD (prior myocardial infarction, stroke, heart failure, or peripheral arterial disease).\n* Males will also be excluded from this study as it focuses on pregnancy related conditions.\n* Children will be excluded as the study is only recruiting people who are 10-20 years postpartum.",{"count":544,"type":21},50,[24],"Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.",[548,549,550],"Hypertension (HTN)","Preeclampsia","Hypertensive Disorders of Pregnancy (HDP)",[552,553,554,555],"hypertension","preeclampsia","coaching","home blood pressure monitoring","2026-07-27",{"date":558,"type":36},"2026-07-29",{"date":560,"type":36},"2026-07-22",{"date":562,"type":21},"2027-10",{"name":42,"class":43},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":580,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":44},"100513156","offset-mechanisms-in-evaluation-of-lumbar-medial-branch-blocks-100513156","NCT05961800","Offset Mechanisms in Evaluation of Lumbar Medial Branch Blocks","OMEGA Study: Offset Mechanisms in Evaluation of Lumbar Medial Branch Block","OMEGA","Inclusion Criteria:\n\n* Scheduled for lumbar MBB in UPMC Pain Management clinics\n* Age \\> 18 years old\n* Predominantly axial chronic low back pain at least 3 months on a daily basis\n* Must meet the minimum criteria for cognitive function using the PROMIS 2-item cognitive screener (\\>3)\n* Low back pain intensity of \\> 3\u002F10\n* Willing and able to receive study-related phone calls\n\nExclusion Criteria:\n\n* History of spine surgery at the level of the lumbar MBB\n* Active worker's compensation or litigation claims\n* New pain and\u002For psychiatric treatments within 2 weeks of enrollment\n* Not fluent in English and\u002For not able to complete the questionnaires\n* Any clinically unstable systemic illness that is judged to interfere with the study",{"count":520,"type":21},[24],"This study examines the relationship between central nervous system (CNS) mechanisms of pain inhibition and the pain relief that occurs following a lumbar medial branch block (MBB).",[576,577,578,579],"Pain, Chronic","Facet Joint Pain","Pain, Procedural","Analgesia",[581,582,583,584,585,586],"lumbar","medial branch block","offset analgesia","onset hyperalgesia","QST","quantitative sensory testing","2026-07-24",{"date":556,"type":36},{"date":590,"type":36},"2023-07-05",{"date":592,"type":21},"2028-06",{"name":42,"class":43},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":601,"minAge":602,"maxAge":603,"enrollmentInfo":604,"targetDuration":4,"studyType":22,"phases":606,"briefSummary":607,"conditions":608,"keywords":613,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":623},"100627625","vasectomy-right-for-me-decision-support-tool-100627625","NCT07451067","\"Vasectomy: Right for Me?\" Decision Support Tool","Addressing Factors Related to Disparities in Vasectomy","Inclusion Criteria:\n\n* Are assigned male at birth\n* 21-55 years of age\n* Comfortable reading in English or Spanish\n* Live in the United States\n* Are considering vasectomy\n* Have not had a vasectomy\n\nExclusion Criteria:\n\n* Are not assigned male at birth\n* Are less than 21 or more than 55 years of age\n* Is not comfortable reading English nor Spanish\n* Do not live in the United States\n* Are not considering vasectomy\n* Have had a vasectomy\n* Once a racial or economic sub-group recruitment number has been reached, no other subjects fitting that ethnicity or income group will be enrolled.","MALE","21 Years","55 Years",{"count":605,"type":21},750,[24],"The goal of this trial is to learn if a web-based decision aid designed to provide evidence-based information about vasectomy and other birth control options helps improve users' decision-making about birth control. The main questions it aims to answer are:\n\n* Do people who use the decision aid have better knowledge about vasectomy?\n* Do people who use the decision aid have lower conflict with their decision?\n\nParticipants will:\n\n* Use the decision aid (if they are assigned to the intervention arm).\n* Answer survey questions about their knowledge, decision-making, interest in vasectomy, and healthcare navigation experiences.",[609,610,611,612],"Vasectomy","Contraception","Contraception Behavior","Reproductive Behavior",[609,614],"Decision aid","2026-07-21",{"date":617,"type":36},"2026-07-23",{"date":619,"type":36},"2026-06-20",{"date":621,"type":21},"2027-08",{"name":42,"class":43},2,{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":17,"minAge":98,"maxAge":99,"enrollmentInfo":632,"targetDuration":4,"studyType":22,"phases":634,"briefSummary":635,"conditions":636,"keywords":639,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":644,"leadSponsor":646,"locationsCount":44},"100629612","differences-in-rest-emotion-and-arousal-modulation-in-youth-100629612","NCT07476937","Differences in Rest, Emotion, and Arousal Modulation in Youth","Probing the Role of Sensory Regulation in Sleep Health and Emotion Dysregulation for Autistic Youth","DREAMY-Autism","Inclusion Criteria:\n\n1. Youth between the ages of 6 and 10 years old\n2. Caregiver-reported autism diagnosis and \\>11 on Social Communication Questionnaire\n3. Caregiver-reported bedtime resistance (\\>12 on Children's Sleep Habits Questionnaire-Autism; Sleep Initiation subscale - 3-point scale, 6 questions)\n4. Caregiver willing to participate in all bedtimes during study\n5. Stable medication use (e.g., no changes within 2 weeks)\n\nExclusion Criteria:\n\n1. Participants will be excluded if they do not understand English or are unable to travel to the lab (Pittsburgh, PA).\n2. Concurrent diagnosis of sleep apnea, narcolepsy, or major psychiatric disorder (e.g., major depression, bipolar).\n3. Unstable medication use (dose or timing).\n4. Current behavioral treatment for sleep disorder",{"count":633,"type":21},60,[24],"The goal of this study is to examine the relationship between sensory responsivity, bedtime arousal levels, sleep disturbances, and daytime emotion dysregulation for autistic children (ages 6-10). In a subset of children with elevated sensory responsivity, a sensory-based bedtime manipulation targeting bedtime arousal levels will be tested.",[105,637,638],"Sleep Disturbances in Children","Sleep",[108,109,110,638,640],"autism","2026-07-20",{"date":560,"type":36},{"date":641,"type":36},{"date":645,"type":21},"2030-08",{"name":42,"class":43},""]